(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.66%.
Atyr Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ATYR's revenue for 2025 to be $1,068,053,232, with the lowest ATYR revenue forecast at $1,068,053,232, and the highest ATYR revenue forecast at $1,068,053,232. On average, 3 Wall Street analysts forecast ATYR's revenue for 2026 to be $2,180,252,664, with the lowest ATYR revenue forecast at $1,121,455,894, and the highest ATYR revenue forecast at $3,017,250,380.
In 2027, ATYR is forecast to generate $8,595,603,407 in revenue, with the lowest revenue forecast at $1,780,088,720 and the highest revenue forecast at $14,570,026,173.